For over three decades, scientists have sought to unravel the natural biosynthetic pathway by which the Pacific yew tree (Taxus brevifolia) produces Taxol. Although the early stages of this pathway were well characterized, the identity of the enzymes catalyzing the crucial final steps remained elusive. This gap impeded the ability to develop sustainable and scalable synthetic biology approaches for Taxol production, forcing dependence on chemically intensive, costly semi-synthesis methods derived from yew bark or needles.

The team at the University of Copenhagen, led by Professor Sotirios Kampranis and Assistant Professor Feiyan Liang, has successfully identified the two missing enzymes that catalyze the final reactions converting precursor molecules into bioactive Taxol. This crucial discovery completes the biochemical map, illuminating the full enzymatic sequence from natural precursors to the finished drug molecule. Their findings, published in the prestigious journal Nature Synthesis, represent a milestone toward biotechnological manufacturing of Taxol.

With the full complement of genes encoding the biosynthetic enzymes now identified, the researchers have bioengineered yeast cells to function as living micro-factories, effectively reconstituting the entire Taxol production pathway in a microbial host. By inserting the gene sequences extracted from the yew tree into Saccharomyces cerevisiae, the team created yeast strains capable of synthesizing Taxol from basic feedstock through fermentation processes. This approach exemplifies the transformative power of synthetic biology in pharmaceutical manufacturing by combining genetic information from plants with the speed and scalability of microbial cell culture.

This innovative yeast-based biosynthesis method promises to dramatically reduce the cost of Taxol, which currently exceeds USD 20,000 per kilogram using traditional chemical semi-synthesis. The University of Copenhagen team projects that refining their biotechnological process could halve current production costs, making this lifesaving drug far more accessible globally, particularly in developing countries where ovarian cancer incidence is rising sharply. The affordability and scalability of microbial fermentation could dismantle price barriers that limit patient access to effective chemotherapies.

Beyond cost savings, this new production pathway offers substantial sustainability benefits compared to conventional methods that rely heavily on chemical solvents and environmentally hazardous steps. The process leverages crude extracts from yew needles rather than pure chemical isolates, which reduces the need for extensive purification and minimizes waste generation. Furthermore, the biological synthesis employs recyclable materials and eliminates harmful reagents traditionally used in chemical production, aligning with green chemistry principles.

The environmental urgency of this breakthrough is underscored by the fact that historically, harvesting Taxol placed immense pressure on wild yew populations. The original extraction method involved stripping the bark from mature yew trees, killing them in the process. Given that yew trees require 70 to 100 years to reach maturity, and that up to two trees were needed for a single treatment dose, this approach was ecologically unsustainable and was eventually abandoned. Although modern semi-synthesis alleviated some pressure, demand growth continues to strain natural resources.

Importantly, this research not only marks a scientific triumph but also opens avenues for the development of spin-out ventures aiming to commercialize biotechnological Taxol. The University of Copenhagen team has filed patents to protect the novel process and is actively engaged in transitioning their research from laboratory innovation to real-world pharmaceutical manufacturing. If successful, these endeavors could set new standards for producing complex natural products via engineered microbes.

Clinically, the ability to produce Taxol more affordably and sustainably has profound implications. Ovarian cancer is expected to increase in prevalence by more than 55% worldwide by 2050, disproportionately impacting low- and middle-income countries. With the mortality rate projected to rise nearly 70% in these regions, affordable access to effective chemotherapy drugs like Taxol is urgent. By enhancing supply through biotechnological means, the barriers created by exorbitant costs could be overcome, potentially saving thousands of lives.

Technically, recreating the complete Taxol pathway in yeast presents remarkable challenges. Taxol’s structure is exceptionally intricate, comprising multiple stereocenters, oxygen functionalities, and side chains that require precise enzymatic steps for assembly. Identifying the final enzymes enabled the closure of the synthetic loop, allowing the microbial host not only to generate intermediates but also to finalize molecular tailoring that renders the molecule biologically active against cancer cells. This sophisticated metabolic engineering reflects the state-of-the-art in pathway elucidation and synthetic biotechnology.

Furthermore, the researchers emphasize that the discovery is just the foundation for further improvements. Ongoing optimization is necessary to boost yield, enhance metabolic flux, and reduce fermentation times to meet industrial production requirements. However, the ability to codify the entire biosynthetic process genetically means programmable, modular manipulation is now possible, offering unparalleled flexibility compared to chemical synthesis.

In summary, this breakthrough signals a new era in chemotherapy drug production marked by sustainability, affordability, and scalability. The convergence of molecular biology, enzymology, and synthetic biology has unlocked a natural biosynthetic code hidden within the yew tree for decades. As biotech-based Taxol production moves from proof-of-concept to commercialization, the oncology community and patients worldwide stand to benefit enormously from more accessible and environmentally responsible therapies.

Subject of Research: Biosynthesis and biotechnological production of the chemotherapy drug Taxol (paclitaxel)

Article Title: Elucidation of the final steps in Taxol biosynthesis and its biotechnological production

News Publication Date: 30-Apr-2025

Web References:

• Nature Synthesis article: https://www.nature.com/articles/s44160-025-00800-z
• Paclitaxel price source: https://www.pharmacompass.com/price/paclitaxel

References:
Kampranis, S., Liang, F., et al. (2025). Elucidation of the final steps in Taxol biosynthesis and its biotechnological production. Nature Synthesis. DOI: 10.1038/s44160-025-00800-z

Image Credits: Yao-Tao Duan, University of Copenhagen

Keywords: Taxol, paclitaxel, cancer chemotherapy, biosynthesis, synthetic biology, metabolic engineering, biotechnological production, yeast fermentation, yew tree, enzymology, synthetic pathway, sustainable drug manufacturing

Stem cells are renowned for their remarkable ability to self-renew and differentiate into specialized cells, such as those forming skin, liver, or nerve tissue. However, as these cells age or under standard laboratory cultures, their potency and functional fitness tend to diminish. The team at Copenhagen identified that by simply replacing glucose, the commonly used sugar in the cell culture medium, with galactose, they could reroute the cells’ energy metabolism. This metabolic shift forces the cells away from the typical glucose-driven glycolysis toward oxidative phosphorylation, a fundamentally different biochemical pathway, known to be more efficient and associated with healthier, less aged cells.

The metabolic reprogramming induced by galactose does more than just change energy production; it triggers molecular signaling cascades critical for controlling the aging process at the cellular level. The researchers discovered activation of a specific class of proteins called NAD+-dependent deacetylases, which play a protective role against cellular senescence. These enzymes enhance the binding of other proteins to DNA, resulting in a more compact and orderly genomic architecture. This modulation of chromatin structure effectively filters out unnecessary genetic “noise,” allowing the stem cells to “hear” their genetic instructions more clearly—a phenomenon described as an improved signal-to-noise ratio.

This enhanced genomic clarity enables the “super stem cells” to revert to what resembles an earlier, more youthful developmental state. Acting as if they originate from an embryonic stage, these reprogrammed cells exhibit an elevated capacity to differentiate into a variety of functional cell types, a fundamental trait for regenerative medicine. Unlike standard stem cells, these metabolically reconditioned cells maintain their health and functional fitness over extended culture periods, an advancement that could overcome some of the key limitations faced by stem cell therapies today.

Beyond the laboratory environment, the potential applications of these findings are vast and far-reaching. The team behind this research envisions harnessing this metabolic trick not only to improve cell therapies for tissue replacement but also to combat degenerative diseases linked to aging. For example, generating revitalized heart or liver cells could pave the way for novel treatments for congestive heart failure and liver cirrhosis, conditions with limited therapeutic options. The implications extend further to neurological disorders such as Parkinson’s disease, osteoporosis, and diabetes, all of which may benefit from stem cell-based regenerative strategies enhanced by this metabolic modulation.

One particularly exciting avenue of exploration lies in the realm of fertility treatment, specifically in vitro fertilization (IVF). The study highlights that these “super stem cells” demonstrate an improved ability to form yolk sac cell lineages, early embryonic tissues critical for successful implantation and development. Given that implantation success remains a major hurdle in IVF, optimizing embryo cultures with these metabolic principles could significantly improve pregnancy outcomes. The researchers are optimistic about translating their findings into culture regimes that better mimic the embryo’s natural metabolic environment, potentially revolutionizing IVF protocols.

The underlying molecular processes offer intriguing insights into the biology of aging and cellular identity. The hallmark of aging stem cells—a compromised signal-to-noise ratio in gene expression—is conceptually likened to the difficulty elderly individuals experience in distinguishing speech within a noisy environment. By reinstating more precise genetic regulation, this metabolic intervention restores stem cells’ developmental “focus,” enabling them to perform their quintessential role more effectively. This represents a pioneering conceptual shift in stem cell biology, linking metabolism tightly with epigenetic control and cellular youthfulness.

In the experimental setup, embryonic stem cells—cultured from mice—were grown in culture media where glucose was replaced by galactose. This subtle nutrient substitution shifted the cells’ metabolic reliance onto oxidative phosphorylation, a more oxygen-dependent and efficient pathway than glycolysis. The oxidative metabolism elevates levels of NAD+, a critical coenzyme that activates sirtuins, the class of NAD+-dependent deacetylases influential in DNA and chromatin remodeling. This leads to a biochemical and structural reprogramming that enhances the cells’ developmental potential and longevity in culture.

The implications of this research extend beyond stem cell biology, touching on fundamental aging mechanisms and metabolic regulation. It underscores how altering cellular metabolism can serve as a master switch to reset cellular identity and function. This approach could redefine how we think about cell culture, tissue engineering, and disease modeling by emphasizing metabolic environment tailoring to improve cell quality and therapeutic potential. The simplicity of the method—a mere replacement of one sugar for another—makes it highly translational, offering a relatively straightforward route for improving current regenerative medicine protocols.

While the study is currently based on mouse embryonic stem cells, the researchers plan to expand their investigations to human cells and other cell types. The goal is to assess whether similar metabolic programming can rejuvenate adult tissue-specific stem cells or even mature cells, broadening the scope of regenerative therapies. If successful, this would present a new paradigm in medicine, wherein cellular rejuvenation is achieved not through genetic modification or complex treatments but via metabolic reeducation.

This extraordinary work also paves the way for intellectual property and commercial development, as indicated by the researchers’ filing of patents related to the use of their engineered metabolic medium for stem cell culture. Such patents could accelerate the adoption of this technology in clinical and industrial settings, amplifying its impact on human health and longevity.

In conclusion, the University of Copenhagen study furnishes compelling evidence that cellular metabolism is not just a background player but a fundamental determinant of stem cell quality and aging. By controlling the energy fuel available to stem cells, researchers can manipulate their developmental state, creating more robust and youthful cells. This discovery heralds a new frontier in regenerative medicine, where simple dietary switches at the cellular level might unlock powerful therapies for aging, degenerative diseases, and infertility challenges.

Scientific curiosity combined with elegant metabolic engineering has thus illuminated a transformative path forward—for stem cells, for medicine, and perhaps for the human lifespan itself.

Subject of Research: Metabolic reprogramming of embryonic stem cells to enhance differentiation and rejuvenation via NAD+-dependent mechanisms.

Article Title: Altering metabolism programs cell identity via NAD+-dependent deacetylation

News Publication Date: April 25, 2025

Web References: https://www.embopress.org/doi/full/10.1038/s44318-025-00417-0

References: R.A. Bone and J.M. Brickman et al., The EMBO Journal, 2025.

Keywords: Stem cells, metabolic reprogramming, oxidative phosphorylation, NAD+, deacetylation, embryonic stem cells, regenerative medicine, aging, IVF, cell differentiation, signal-to-noise ratio, chromatin remodeling